- Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
- Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
- Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
More ▼
Key statistics
On Friday, Alpha Tau Medical Ltd (DRTS:NAQ) closed at 2.83, 31.62% above the 52 week low of 2.15 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.67 |
---|---|
High | 3.14 |
Low | 2.67 |
Bid | 2.70 |
Offer | 3.06 |
Previous close | 2.67 |
Average volume | 32.70k |
---|---|
Shares outstanding | 69.67m |
Free float | 51.75m |
P/E (TTM) | -- |
Market cap | 184.63m USD |
EPS (TTM) | -0.4203 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼